The Transnational Institute (TNI) organized an expert seminar on Costs and Benefits of Cannabis Regulation Models in Europe in Amsterdam, The Netherlands on October 31/November 1, 2013. The objective of the seminar was to identify and map existing and possible future cannabis regulation models in Europe, looking at the local, provincial and national levels and the potential impact of such models on the illicit cannabis market.
This is a guide to regulating legal markets for the non-medical use of cannabis. It is for policy makers, drug policy reform advocates and affected communities all over the world, who are witnessing the question change from, 'Should we maintain cannabis prohibition?' to 'How will legal regulation work in practice?
Since first coming to public prominence at the end of 2009, legal highs have posed a major challenge to existing legal and legislative structures designed to deal with drugs. With the market in manufactured psychoactive substances like mephedrone moving faster than public policy can accommodate, this report asks whether the assumptions enshrined in the 40-year-old Misuse of Drugs Act (MDA) are still valid when applied 21st century drugs market.
Beau Kilmer, Jonathan P. Caulkins, Rosalie Liccardo Pacula, Robert J. MacCoun, Peter H. Reuter
07 July 2010
To learn more about the possible outcomes of marijuana legalization in California, RAND researchers constructed a model based on a series of estimates of current consumption, current and future prices, how responsive use is to price changes, taxes levied and possibly evaded, and the aggregation of nonprice effects (such as a change in stigma).
Uruguay's approval of regulation under state control marks a tipping point in the failed war against drugs as it makes Uruguay the first country in the world to fully regulate the cultivation, trade and consumption of cannabis for medical, industrial as well as recreational purposes. This infographic gives a quick summary of the reasons why Uruguay is regulating cannabis.
Latin America has emerged at the vanguard of efforts to promote debate on drug policy reform. For decades, Latin American governments largely followed the drug control policies and programs of Washington’s so-called war on drugs. Yet two parallel trends have resulted in a dramatic change in course: the emergence of left-wing governments that have challenged Washington’s historic patterns of unilateralism and interventionism and growing frustration with the failure of the prohibitionist drug control model put forward by the US government.
Beau Kilmer, Jonathan P. Caulkins, Brittany M. Bond, Peter H. Reuter
13 October 2010
The United States’ demand for illicit drugs creates markets for Mexican drug trafficking organizations (DTOs) and helps foster violence in Mexico. Some government and media sources have reported that Mexican and Colombian DTOs combined earn $18–$39 billion annually in wholesale drug proceeds and 60 percent of all Mexican DTO drug export revenue comes from marijuana. These numbers have been cited to argue that legalizing marijuana in California would reduce Mexican DTOs’ revenues, thereby reducing violence.
On December 10, 2013, the General Assembly of Uruguay approved a law that made the country the first one in the world to fully regulate the cultivation, trade and consumption of cannabis for medical, industrial as well as recreational purposes. This infographic gives a short overview of the main aspects of the new law.
How does national legislation in different EU member states compare and how effective is the adding of new psychoactive substances (NPS) to the existing schedules of drug laws versus legislative experimentation designing new schedules or applying controls under medicines or consumer protection regulations?
The New Zealand Law Commission was asked to address the efficacy of the Misuse of Drugs Act in reducing the demand for, and supply of, drugs prohibited under the International Drug Conventions. The Commission has recommended the existing Act be repealed and replaced by a new Act administered by the Ministry of Health. Justice Hammond said the thrust of the proposed new Act is to facilitate a more effective interface between the criminal justice and health sectors: “We need to recognise that the abuse of drugs is both a health and a criminal public policy problem.”
Latin America is now at the vanguard of international efforts to promote drug policy reform: Bolivia has rewritten its constitution to recognize the right to use the coca leaf for traditional and legal purposes, Uruguay has become the first nation in the world to adopt a legal, regulated Cannabis market, and Colombia, Mexico, Guatemala, and Ecuador are openly critiquing the prevailing international drug control paradigm at the UN. And now with the United States itself relaxing its marijuana laws state by state, the U.S. prohibitionist drug war strategies are losing credibility in the region.
Within the last decade the hitherto little known psychoactive substance of khat has emerged as a regional and international issue. In the Horn of Africa khat production has spurred an economic boom, but dramatic increases in consumption have raised public health concerns. Given the complexity of the topic spanning multiple academic disciplines and fields of professional practice, the need for a systematic overview is urgent.
Despite efforts by governments in Latin America, illicit drugs continue to provide one of the largest incomes for criminal organizations, enabling them to penetrate and corrupt political and social institutions.
Cannabis was condemned by the 1961 Single Convention on Narcotic Drugs as a psychoactive drug with “particularly dangerous properties” and hardly any therapeutic value. Ever since, an increasing number of countries have shown discomfort with the treaty regime’s strictures through soft defections, stretching its legal flexibility to sometimes questionable limits.
The CATO report estimates that legalizing drugs would save roughly $41.3 billion per year in government expenditure on enforcement of prohibition. Of these savings, $25.7 billion would accrue to state and local governments, while $15.6 billion would accrue to the federal government. Approximately $8.7 billion of the savings would result from legalization of marijuana and $32.6 billion from legalization of other drugs.
Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate continues on the decriminalisation, or even legalisation, of drugs, particularly cannabis. Models under development for the legal supply of cannabis are described in this analysis, as well as some of the questions they raise.
Part of the ‘Perspectives on drugs’ (PODs) series, launched alongside the annual European Drug Report, these designed-for-the-web interactive analyses aim to provide deeper insights into a selection of important issues.
A grey area has emerged between what is legal and what is not as states struggle with how to respond to the many new synthetic compounds emerging onto the market. Of the various types of ‘Legal highs’ the seminar focused on stimulants because of the parallels with the other main drug-policy issue of the moment; i.e. the status of traditional herbal stimulants. These older discussions have been reinvigorated by: Bolivia’s efforts to de-schedule coca-leaf at UN level; the debates on the status of khat between EU States, and of kratom across Asia; and the increasing stride of legitimate cannabis use on the domestic front, as in for example Spain.
Economists have been among the leading critics of current drug policies, but this criticism does not mean they have reached a consensus about specific reforms. Although drug-policy researchers and economists in general seem opposed to prohibition, they are timid in their advocacy of decriminalization and even less supportive of legalization.